Zhonghua Zhong Liu Za Zhi. 2021 Oct 23;43(10):1007-1015. doi: 10.3760/cma.j.cn112152-20210709-00505.
Bone is a common metastatic site of renal cell carcinoma (RCC), with about 30% of metastatic RCC patients are suffering from bone metastasis. More than 70% of RCC patients with bone metastasis may experience skeletal related events (SREs), which may severely impair patients' quality of life and even shorten their survival time. Therefore, SREs prevention has become one of the treatment objectives of RCC bone metastasis. Bone-modifying agents are the basic treatment of bone metastases in addition to anti-tumor therapy. The treatment of RCC bone metastasis also requires multi-disciplinary team and individualized comprehensive treatment strategies. To standardize the diagnosis and treatment of RCC bone metastasis in China, the expert group of Genitourinary Oncology Committee, Chinese Anti-cancer Association has formulated the expert consensus for the reference of clinical practice, to improve the general therapeutic level of RCC with bone metastasis and benefit more patients.
骨是肾细胞癌（RCC）常见的转移部位，约30%的转移性RCC患者会发生骨转移。超过70%的RCC骨转移患者可能会出现骨相关事件（SREs），这可能严重损害患者的生活质量，甚至缩短其生存时间。因此，预防SREs已成为RCC骨转移的治疗目标之一。除抗肿瘤治疗外，骨改良剂是骨转移的基本治疗方法。RCC骨转移的治疗还需要多学科团队和个体化的综合治疗策略。为规范我国RCC骨转移的诊断和治疗，中国抗癌协会泌尿生殖肿瘤专业委员会专家组制定了专家共识，供临床实践参考，以提高RCC骨转移的总体治疗水平，使更多患者受益。
